F. Ciardiello and G. Tortora, EGFR Antagonists in Cancer Treatment, New England Journal of Medicine, vol.358, issue.11, pp.1160-74, 2008.
DOI : 10.1056/NEJMra0707704

K. Roepstorff, M. Grandal, L. Henriksen, S. Knudsen, M. Lerdrup et al., Differential Effects of EGFR Ligands on Endocytic Sorting of the Receptor, Traffic, vol.14, issue.8, pp.1115-1142, 2009.
DOI : 10.1111/j.1600-0854.2009.00943.x

P. Huang, A. Xu, and F. White, Oncogenic EGFR Signaling Networks in Glioma, Science Signaling, vol.2, issue.87, p.6, 2009.
DOI : 10.1126/scisignal.287re6

G. Guo, K. Gong, B. Wohlfeld, K. Hatanpaa, D. Zhao et al., Ligand-Independent EGFR Signaling, Cancer Research, vol.75, issue.17, pp.3436-3477, 2015.
DOI : 10.1158/0008-5472.CAN-15-0989
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558210

D. Hardbower, K. Singh, M. Asim, T. Verriere, D. Olivares-villagomez et al., EGFR regulates macrophage activation and function in bacterial infection, Journal of Clinical Investigation, vol.126, issue.9, pp.3296-312, 2016.
DOI : 10.1172/JCI83585DS1
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004944

N. Lu, L. Wang, H. Cao, L. Liu, L. Van-kaer et al., Activation of the Epidermal Growth Factor Receptor in Macrophages Regulates Cytokine Production and Experimental Colitis, The Journal of Immunology, vol.192, issue.3, pp.1013-1036, 2014.
DOI : 10.4049/jimmunol.1300133

T. Lynch, Predictive tests for EGFR inhibitors, Clin Adv Hematol Oncol, vol.3, issue.9, pp.678-687, 2005.

F. Cappuzzo, T. Ciuleanu, L. Stelmakh, S. Cicenas, A. Szczesna et al., Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study, The Lancet Oncology, vol.11, issue.6, pp.521-530, 2010.
DOI : 10.1016/S1470-2045(10)70112-1

U. Gatzemeier, A. Pluzanska, A. Szczesna, E. Kaukel, J. Roubec et al., Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non???Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial, Journal of Clinical Oncology, vol.25, issue.12, pp.1545-52, 2007.
DOI : 10.1200/JCO.2005.05.1474

N. Zhao, X. Zhang, H. Yan, J. Yang, Y. Wu et al., Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials A chromatinmediated reversible drug-tolerant state in cancer cell subpopulations, Lung Cancer. Cell. Science, vol.85141316, issue.125827, pp.66-7369, 2007.

K. Politi and R. Herbst, Lung Cancer in the Era of Precision Medicine, Clinical Cancer Research, vol.21, issue.10, pp.2213-2233, 2015.
DOI : 10.1158/1078-0432.CCR-14-2748

T. Yoshida, I. Okamoto, T. Iwasa, M. Fukuoka, and K. Nakagawa, The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF, FEBS Letters, vol.6, issue.30, pp.4125-4155, 2008.
DOI : 10.1016/j.febslet.2008.11.010

J. Hanke, J. Gardner, R. Dow, P. Changelian, W. Brissette et al., Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor: STUDY OF Lck- AND FynT-DEPENDENT T CELL ACTIVATION, Journal of Biological Chemistry, vol.271, issue.2, pp.695-701, 1996.
DOI : 10.1074/jbc.271.2.695

T. Chou, J. Engelman, P. Janne, C. Mermel, J. Pearlberg et al., Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines, Pharmacological reviews. Proceedings of the National Academy of Sciences of the United States of America, vol.58102, issue.1710, pp.621-813788, 2005.

E. Ametller, S. Garcia-recio, E. Pastor-arroyo, G. Callejo, N. Carbo et al., Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays, Cancer Biol Ther. Molecular cancer therapeutics. Sci Signal, vol.1158, issue.20359, pp.4-131154, 2006.

S. Kopetz, R. Bonavia, A. Mukasa, Y. Narita, D. Sah et al., Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma, Gastrointest Cancer Res. Inda MM Genes & development, vol.124, issue.2216, pp.37-411731, 2007.

D. Decaudin, Primary human tumor xenografted models ('tumorgrafts') for good management of patients with cancer. Anti-cancer drugs, pp.827-868, 2011.

E. Stewart, C. Mascaux, N. Pham, S. Sakashita, J. Sykes et al., -Mutant Lung Adenocarcinoma, Journal of Clinical Oncology, vol.33, issue.22, pp.2472-80, 2015.
DOI : 10.1200/JCO.2014.60.1492
URL : https://hal.archives-ouvertes.fr/hal-01058773

H. Gao, J. Korn, S. Ferretti, J. Monahan, Y. Wang et al., High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response, Nature Medicine, vol.9, issue.11, pp.1318-1343, 2015.
DOI : 10.1038/nbt.1549

S. Chakraborty, L. Li, V. Puliyappadamba, G. Guo, K. Hatanpaa et al., Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks, Nature Communications, vol.83, pp.5811-5838, 2014.
DOI : 10.1038/ncomms6811
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268886

I. Arany, J. Megyesi, H. Kaneto, P. Price, and R. Safirstein, Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells, AJP: Renal Physiology, vol.287, issue.3, pp.543-552, 2004.
DOI : 10.1152/ajprenal.00112.2004

Q. Dai, Y. Ling, L. M. Zou, Y. Kroog, G. Iwata et al., Enhanced Sensitivity to the HER1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Hydrochloride in Chemotherapy-Resistant Tumor Cell Lines, Clinical Cancer Research, vol.11, issue.4, pp.1572-1580, 2005.
DOI : 10.1158/1078-0432.CCR-04-0993

J. Kwon, H. Yoon, J. Kim, T. Lee, I. Song et al., Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma, Oncology reports, vol.32, issue.3, pp.1188-92, 2014.

R. Osarogiagbon, F. Cappuzzo, T. Ciuleanu, L. Leon, and B. Klughammer, Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. Translational lung cancer research, pp.465-74, 2015.

S. Cicenas, S. Geater, P. Petrov, Y. Hotko, G. Hooper et al., Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study) Lung Cancer Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy, Ann Oncol, vol.1022319, issue.33, pp.30-7388, 2011.

L. Salvia, A. Rossi, A. Galetta, D. Gobbini, E. et al., Intercalated Chemotherapy and Epidermal Growth Factor Receptor Inhibitors for Patients With Advanced Non???Small-cell Lung Cancer: A Systematic Review and Meta-analysis, Clinical Lung Cancer, vol.18, issue.1, pp.23-33, 2017.
DOI : 10.1016/j.cllc.2016.08.006

F. Janku, D. Stewart, and R. Kurzrock, Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nature reviews Clinical oncology, pp.401-415, 2010.

C. Addison, K. Ding, H. Zhao, L. Maitre, A. Goss et al., Plasma Transforming Growth Factor ?? and Amphiregulin Protein Levels in NCIC Clinical Trials Group BR.21, Journal of Clinical Oncology, vol.28, issue.36, pp.5247-56, 2010.
DOI : 10.1200/JCO.2010.31.0805

N. Ishikawa, Y. Daigo, A. Takano, M. Taniwaki, T. Kato et al., Increases of Amphiregulin and Transforming Growth Factor-?? in Serum as Predictors of Poor Response to Gefitinib among Patients with Advanced Non-Small Cell Lung Cancers, Cancer Research, vol.65, issue.20, pp.9176-84, 2005.
DOI : 10.1158/0008-5472.CAN-05-1556

L. Galluzzi, I. Vitale, L. Senovilla, T. Eisenberg, D. Carmona-gutierrez et al., Independent transcriptional reprogramming and apoptosis induction by cisplatin, Cell Cycle, vol.267, issue.18, pp.3472-80, 2012.
DOI : 10.1038/emboj.2010.11
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466557

S. Huang, E. Armstrong, S. Benavente, P. Chinnaiyan, and P. Harari, Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR): Combining Anti-EGFR Antibody with Tyrosine Kinase Inhibitor, Cancer Research, vol.64, issue.15, pp.5355-62, 2004.
DOI : 10.1158/0008-5472.CAN-04-0562

P. Matar, F. Rojo, R. Cassia, G. Moreno-bueno, D. Cosimo et al., Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225): Superiority Over Single-Agent Receptor Targeting, Clinical Cancer Research, vol.10, issue.19, pp.6487-501, 2004.
DOI : 10.1158/1078-0432.CCR-04-0870

L. Regales, Y. Gong, R. Shen, E. De-stanchina, I. Vivanco et al., Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer, Journal of Clinical Investigation, vol.119, issue.10, pp.3000-3010, 2009.
DOI : 10.1172/JCI38746DS1

Y. Janjigian, E. Smit, H. Groen, L. Horn, S. Gettinger et al., Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations, Cancer Discovery, vol.4, issue.9, pp.1036-1081, 2014.
DOI : 10.1158/2159-8290.CD-14-0326

A. Weickhardt, T. Price, G. Chong, V. Gebski, N. Pavlakis et al., Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival, J Clin Oncol. J Clin Oncol. Cancer Cell, vol.302915, issue.456, pp.1505-124113, 2009.

N. Ihle, L. Byers, E. Kim, P. Saintigny, J. Lee et al., Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome, JNCI: Journal of the National Cancer Institute, vol.104, issue.3, pp.228-267, 2012.
DOI : 10.1093/jnci/djr523